Paclitaxel-based strategy as first-line therapy for advanced breast cancer: a model-based economic evaluation for China
At the WTP threshold of $37,721.52/QALY in China, ABPTX is more cost-effective than PTXPM under equivalent efficacy and safety, from the Chinese healthcare perspective.
Authors
- Jia Hu (ORCID: https://orcid.org/0000-0002-8844-6116)
- Jisheng Chen (ORCID: https://orcid.org/0000-0003-3514-9086)
- Mengting Li (ORCID: https://orcid.org/0000-0001-5894-757X)
Institutions
- Third People's Hospital of Chengdu (CN)
- First People's Hospital of Foshan (CN)
- First Affiliated Hospital of Guangdong Pharmaceutical University (CN)
Publication Details
- Journal
- Future Oncology
- Published
- 2025-08-26
- DOI
- https://doi.org/10.1080/14796694.2025.2550832
- Citations
- 1
- Primary Topic
- Cancer Treatment and Pharmacology
- Type
- article
- Field-Weighted Citation Impact
- 1.05